Effect of alogliptin on albuminuria in patients with early type 2 diabetic nephropathy and related mechanism
10.3760/cma.j.issn.1671-7368.2019.03.007
- VernacularTitle:阿格列汀对早期2型糖尿病肾病患者尿蛋白的影响
- Author:
Wencong LI
1
;
Hong MIAO
;
Lei ZHU
;
Jinpeng MA
;
Xiangxiang WANG
;
Li ZHANG
;
Peng FU
;
Haijiao WANG
;
Hao LI
;
Weiwei XIAO
Author Information
1. 山东省立第三医院内分泌科
- Keywords:
Diabetic nephropathies;
Dipeptidyl-peptidase Ⅳ inhibitors;
Urinary albumin-to-creatinineratio;
Albuminuria;
Stromal cell-derived factor-1α
- From:
Chinese Journal of General Practitioners
2019;18(3):241-245
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of alogliptin on albuminuria in patients with early type 2 diabetic kidney disease (DKD) and the related mechanism.Methods One hundred patients with early DKD admitted in our hospital from May 2016 to May 2017 were randomly divided into two groups with 50 cases in each group.Patients in the control group were given metformin and gliclazide,while those in study group were given metformin and alogliptin,the treatment lasted for 24 weeks.The changes of urinary albumin-to-creatinine ratio (UACR),stromal cell-derived factor-1α (SDF-1α) and the fasting plasma glucose (FPG),2-h postprandial plasma glucose (2 hPPG),glycosylated hemoglobin(HbA1c) were measured before and after the treatment in two groups.Results There were no significant differences in HbA1c [(8.17± 0.46)％ vs.(8.29±0.48)％],UACR[(109±53) vs.(105±48)mg/g],SDF-1α [(1.21±0.3 9) vs.(1.17±0.35)μg/L] levels before treatment between two groups (t=0.343,0.464,0.075,all P＞0.05).After treatment,the HbA1c levels were significantly decreased in both groups (t=2.293,2.302,all P=0.03) and there was no significant difference between two groups[(6.82±0.75)％ vs.(6.93 ±0.79)％,t=0.295,P=0.77];the UACR levels were significantly reduced in both groups,but the level of study group was significantly lower than that of control group [(82±38) vs.(94±47) mg/g,t=3.320,P＜0.01];the SDF-1α levels were significantly increased in both groups,but the level of study group was significantly higher than that of control group[(3.01 ±0.38) vs.(2.76±0.42)μg/L,t=5.474,P＜0.01].There was no significant difference in the incidence of adverse reactions between the two groups [13％ (6/46) vs.12％ (6/48),x2=0.002,P＞0.05].Conclusion Alogliptin can effectively control the blood glucose,reduce urine albumin excretion and protect renal function in patients with early type 2 diabetic nephropathy,which is associated with the increased SDF-1α levels.
